Trials / Completed
CompletedNCT05863273
Real World Study on the Efficacy and Safety of Apremilast in Chinese Patients With Moderate to Severe Plaque Psoriasis, a Multi Center, Prospective, Observational Trial（REACT）
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 360 (actual)
- Sponsor
- First Hospital of China Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, one-arm, prospective, observational study，intended to assess evaluation of efficacy and safety of Apremilast in Chinese patients with moderate-to-severe plaque psoriasis。During this study, it is expected to collect data at at baseline and weeks 2, 6, 10, 16, and 20 after treatment。
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apremilast | Dosage of Apremilast（Otezla®） from 10mg qd, titrate to recommended dosage of 30 mg BID，recommended by specification. |
Timeline
- Start date
- 2023-05-22
- Primary completion
- 2025-02-10
- Completion
- 2025-03-10
- First posted
- 2023-05-18
- Last updated
- 2025-03-17
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05863273. Inclusion in this directory is not an endorsement.